Dendritic Cells and Cancer Immunity

By Alycia Gardner, B. Ruffell. Trends in immunology, 2016

756 citations recorded by the source corpus.

Dendritic cells (DCs) are central regulators of the adaptive immune response, and as such are necessary for T cell-mediated cancer immunity. In particular, anti-tumoral responses depend upon a specialized subset of conventional DCs that transport tumor antigens to draining lymph nodes and cross-present antigen to activate cytotoxic T lymphocytes. DC maturation is necessary to provide co-stimulatory signals to T cells, but while DC maturation occurs within tumors, it is often insufficient to induce potent immunity, particularly in light of suppressive mechanisms within tumors. Bypassing suppressive pathways or directly activating DCs can unleash a T cell response, and although clinical efficacy has proven elusive, therapeutic targeting of DCs continues to hold translational potential in combinatorial approaches.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/b7cc48b6031d096362f8edf0778f6d701d6dd43c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Muyue Yang
2. Xianqun Fan
3. Jipeng Li
4. P. Gu

Citations in the corpus

• The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment (2020, background): “Conventional DCs (cDCs), one subset of the DC lineage, are thought to be closely associated with tumor development, which internalize tumor-associated antigens and deliver them to draining lymph nodes [28], activating immunity against tumor.”